This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula I



I

in which

R^2, R^4 denote H, A, Hal, cycloalkyl having 3 to 7 C atoms, CF_3, NO_2, CN, OCF_3, OA, NHA, NA_2, or NH_2,

R^6 is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro- , dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl,

R^3 is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl,

R^1 denotes ~~H or~~ CO_2R^5, $(CH_2)_nCOHet$, CHO, $(CH_2)_nOR^5$, $(CH_2)_nHet$, $(CH_2)_nN(R^5)_2$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_n(R^5)Het$, $(CH_2)_nCH$=N-Het, $(CH_2)_nOCOR'$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2CH_2OCF_3$,

$(CH_2)_nN(R^5)C(R^5)OCOR^5$, $(CH_2)_nN(R')CH_2COHet$, $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2N(R')CH_2OCOR'$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$, $CH=CHCOOR^5$, $CH=CHCH_2NR^5Het$, $CH=CHCH_2N(R^5)_2$, $CH=CHCH_2OR^5$ or $(CH_2)_nN(R^5)Ar$,

R^5 denotes H or A

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, or alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,

Het is 1-piperidyl, 1-piperazyl, 1-(4-methyl)piperazyl, 1-(4-ethyl)piperazinyl, 1-(4-cyclopentyl)piperazinyl, 4-methylpiperazin-1-ylamine, 1-pyrrolidinyl, 1-pyrazolidinyl 1-(2-methyl)pyrazolidinyl, 1-imidazolidinyl or 1-(3-methyl)imidazolidinyl or 4-pyridyl, which is unsubstituted or substituted by one or more CN group, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, or a group of one of the formulae below



	
	
	
	
	
	
	
	

	
	
	
	
	
	
	

	
	
	
	
	
	
	
	

	
	
	
	
	
	
	



Ar denotes a phenyl radical which is unsubstituted or mono or polysubstituted by A and/or Hal, OR^5, $OOCR^5$, $COOR^5$, $CON(R^5)_2$, CN, NO_2, NH_2, $NHCOR^5$, CF_3 or SO_2CH_3,

X denotes CH or N,

n denotes 0, 1, 2, 3, 4 or 5 and

Hal denotes F, Cl, Br or I,

where, in the case that X has the meaning CH, R^2 and R^4 do not simultaneously denote H,

or a salt, enantiomer, or racemate thereof, or a mixture of enantiomers.

2. (Cancelled)

3. (Currently Amended) A compound according to claim 28 [[1]], in which R^4 denotes H, Hal, CN, A or NO_2.

4. (Currently Amended) A compound according to claim 28 [[1]], in which R^2 denotes H or alkyl.

5. (Cancelled)

6. (Previously Presented) A compound according to claim 1, in which X has the meaning N.

7. (Currently Amended) A compound of formula IA, IB, IC, ID, IE or IF:



IA



IB



IC



ID



IE



IF

in which

R^3 is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl,

R^4 denote H, A, Hal, cycloalkyl having 3 to 7 C atoms, CF_3, NO_2, CN, OCF_3, OA, NHA, NA_2, or NH_2,

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, or alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,

Hal denotes F, Cl, Br or I,

X denotes CH or N,

where, in the case that X has the meaning CH, R^4 in the compounds of formulae IA, IC and IE does not denote H, and

R^6 is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro- , dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl

~~R^3, R^4, R^6 and X have the meanings indicated for the compound of formula I~~.

8. (Previously Presented) A process for preparing a compound of claim 1, which is of formula IA



IA

in which R^3, R^4, R^6, X and A have the meaning indicated for the compound of formula I or a salt thereof,
comprising reacting a compound of formula II



II

or an acid-addition salt thereof,

in which R^4, R^6 and X have the meanings indicated for the compound of formula I,

with a compound of formula III



III

in which A and R^3 have the meanings indicated for the compound of formula I,

and/or converting a basic compound of formula IA into one of its salts by treatment with an acid.

9. (Currently Amended) A process for preparing a compound ~~of claim 1, which is~~ of formula IB



IB

in which

R^3 is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-,

n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl,

R^4 denote H, A, Hal, cycloalkyl having 3 to 7 C atoms, CF_3, NO_2, CN, OCF_3, OA, NHA, NA_2, or NH_2,

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, or alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,

Hal denotes F, Cl, Br or I,

X denotes CH or N,

R^6 is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro- , dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl,

~~R^3, R^4, R^6, X and A have the meaning indicated for the compound of formula I~~

or a salt thereof,

comprising reacting a compound of formula II



II

or an acid-addition salt thereof,

in which R^4, R^6 and X have the meanings indicated for the compound of formula IB ~~formula I~~,

with a compound of formula IV



IV

in which A and R^3 have the meanings indicated for the compound of formula IB ~~formula I~~, and/or converting a basic compound of formula IB into one of its salts by treatment with an acid.

10-13. (Cancelled)

14. (Currently Amended) A pharmaceutical composition comprising at least one compound of the formula I ~~according to claim 1~~ and/or one of its physiologically acceptable salts, and a pharmaceutically acceptable carrier,



I

in which

R^2, R^4 denote H, A, Hal, cycloalkyl having 3 to 7 C atoms, CF_3, NO_2, CN, OCF_3, OA, NHA, NA_2, or NH_2,

R^6 is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro- , dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl,

R^3 is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl,

R^1 denotes H or CO_2R^5, $(CH_2)_nCOHet$, CHO, $(CH_2)_nOR^5$, $(CH_2)_nHet$, $(CH_2)_nN(R^5)_2$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_n(R^5)Het$, $(CH_2)_nCH$=N-Het, $(CH_2)_nOCOR'$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2CH_2OCF_3$, $(CH_2)_nN(R^5)C(R^5)OCOR^5$, $(CH_2)_nN(R')CH_2COHet$, $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2N(R')CH_2OCOR'$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$, $CH=CHCOOR^5$, $CH=CHCH_2NR^5Het$, $CH=CHCH_2N(R^5)_2$, $CH=CHCH_2OR^5$ or $(CH_2)_nN(R^5)Ar$,

R^5 denotes H or A

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, or alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,

Het is 1-piperidyl, 1-piperazyl, 1-(4-methyl)piperazyl, 1-(4-ethyl)piperazinyl, 1-(4-cyclopentyl)piperazinyl, 4-methylpiperazin-1-ylamine, 1-pyrrolidinyl, 1-pyrazolidinyl 1-(2-methyl)pyrazolidinyl, 1-imidazolidinyl or 1-(3-methyl)imidazolidinyl or 4-pyridyl, which is unsubstituted or substituted by one or more CN group, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, or a group of one of the formulae below

	
	
	
	
	
	
	
	

	
	
	
	
	
	
	

	
	
	
	
	
	
	

	
	
	
	
	
	
	

	
	
	
	
	 or
	

Ar denotes a phenyl radical which is unsubstituted or mono or polysubstituted by A and/or Hal, OR^5, $OOCR^5$, $COOR^5$, $CON(R^5)_2$, CN, NO_2, NH_2, $NHCOR^5$, CF_3 or

SO_2CH_3,

X denotes CH or N,

n denotes 0, 1, 2, 3, 4 or 5 and

Hal denotes F, Cl, Br or I,

where, in the case that X has the meaning CH, R^2 and R^4 do not simultaneously denote H,

or a salt, enantiomer, or racemate thereof, or a mixture of enantiomers.

15. (Currently Amended) A process for the preparation of a pharmaceutical composition, comprising combining a compound of the formula I according to Claim 14 [[1]] and/or one of its physiological acceptable salts into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

16. (Cancelled)

17. (Currently Amended) A compound according to claim 28 [[1]], in which Het is





18. (Cancelled)

19. (Currently Amended) A method for the *in vitro* inhibition of 5-HT2A receptor, comprising administering to said receptor a pharmaceutical composition according to claim 14 ~~compound, salt, enantiomer, racemate or enantiomer mixture of claim 1~~.

20. (Currently Amended) A compound according to claim 1, in which R^1 denotes denotes ~~H or~~ $(CH_2)_nCOHet$, CHO, $(CH_2)_nOR^5$, $(CH_2)_nHet$, $(CH_2)_nN(R^5)_2$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_n(R^5)Het$, $(CH_2)_nCH$=N-Het, $(CH_2)_nOCOR'$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2CH_2OCF_3$, $(CH_2)_nN(R^5)C(R^5)OCOR^5$, $(CH_2)_nN(R')CH_2COHet$, $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2N(R')CH_2OCOR'$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$, $CH=CHCOOR^5$, $CH=CHCH_2NR^5Het$, $CH=CHCH_2N(R^5)_2$, $CH=CHCH_2OR^5$ or $(CH_2)_nN(R^5)Ar$.

21. (Currently Amended) A compound according to claim 1, in which R^1 denotes denotes ~~H or~~ CO_2R^5, COHet, CHO, $(CH_2)_nOR^5$, $(CH_2)_nHet$, $(CH_2)_nN(R^5)_2$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_n(R^5)Het$, $(CH_2)_nCH$=N-Het, $(CH_2)_nOCOR'$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2CH_2OCF_3$, $(CH_2)_nN(R^5)C(R^5)OCOR^5$, $(CH_2)_nN(R')CH_2COHet$, $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2N(R')CH_2OCOR'$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$, $CH=CHCOOR^5$, $CH=CHCH_2NR^5Het$, $CH=CHCH_2N(R^5)_2$, $CH=CHCH_2OR^5$ or $(CH_2)_nN(R^5)Ar$.

22. (Currently Amended) A compound according to claim 1, in which R^1 denotes denotes ~~H or~~ $(CH_2)_nHet$, $(CH_2)_nN(R^5)_2$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$,

$(CH_2)_n(R^5)Het$, $(CH_2)_nCH=N\text{-}Het$, $(CH_2)_nOCOR'$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2CH_2OCF_3$, $(CH_2)_nN(R^5)C(R^5)OCOR^5$, $(CH_2)_nN(R')CH_2COHet$, $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2N(R')CH_2OCOR'$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$, $CH=CHCOOR^5$, $CH=CHCH_2NR^5Het$, $CH=CHCH_2N(R^5)_2$, $CH=CHCH_2OR^5$ or $(CH_2)_nN(R^5)Ar$.

23. (Previously Presented) A compound according to claim 1 or a pharmaceutically acceptable salt thereof.

24. (Previously Presented) A compound according to claim 1, in which R^3 is thiophen-2-yl or thiophen-3-yl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl.

25. (Previously Presented) A compound according to claim 1, in which R^3 is 2- or 3-furanyl.

26. (New) A compound according to claim 1, in which R^4 denote A, Hal, cycloalkyl having 3 to 7 C atoms, CF_3, NO_2, CN, OCF_3, OA, NHA, NA_2, or NH_2.

27. (New) A compound according to claim 1, in which A denotes straight-chain or branched alkyl or alkoxy having 3 to 10 C atoms, or alkenyl or alkenyloxyalkyl having 3 to 10 C atoms.

28. (New) A compound of formula I



I

in which

R^2, R^4 denote H, A, Hal, cycloalkyl having 3 to 7 C atoms, CF_3, NO_2, CN, OCF_3, OA, NHA, NA_2, or NH_2,

R^6 is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro- , dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl,

R^3 is phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl or 2- or 3-furanyl,

R^1 denotes H or CO_2R^5, $(CH_2)_nCOHet$, CHO, $(CH_2)_nOR^5$, $(CH_2)_nHet$, $(CH_2)_nN(R^5)_2$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_n(R^5)Het$, $(CH_2)_nCH$=N-Het, $(CH_2)_nOCOR'$, $(CH_2)_nN(R^5)CH_2CH_2OR^5$, $(CH_2)_nN(R^5)CH_2CH_2OCF_3$, $(CH_2)_nN(R^5)C(R^5)OCOR^5$, $(CH_2)_nN(R')CH_2COHet$, $(CH_2)_nN(R^5)CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2Het$, $(CH_2)_nN(R^5)CH_2CH_2N(R')CH_2OCOR'$, $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$, $CH=CHCOOR^5$, $CH=CHCH_2NR^5Het$, $CH=CHCH_2N(R^5)_2$, $CH=CHCH_2OR^5$ or $(CH_2)_nN(R^5)Ar$,

R^5 denotes H or A

A denotes straight-chain or branched alkyl or alkoxy having 1 to 10 C atoms, or alkenyl or alkenyloxyalkyl having 2 to 10 C atoms,

Het is 1-piperidyl, 1-piperazyl, 1-(4-methyl)piperazyl, 1-(4-ethyl)piperazinyl, 1-(4-cyclopentyl)piperazinyl, 4-methylpiperazin-1-ylamine, 1-pyrrolidinyl, 1-pyrazolidinyl

1-(2-methyl)pyrazolidinyl, 1-imidazolidinyl or 1-(3-methyl)imidazolidinyl or 4-pyridyl, which is unsubstituted or substituted by one or more CN group, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, or a group of one of the formulae below

	
	
	
	
	
	
	

	
	
	
	
	
	
	
	

	
	
	
	
	
	
	

	
	
	
	
	
	
	



Ar denotes a phenyl radical which is unsubstituted or mono or polysubstituted by A and/or Hal, OR^5, $OOCR^5$, $COOR^5$, $CON(R^5)_2$, CN, NO_2, NH_2, $NHCOR^5$, CF_3 or SO_2CH_3,

X denotes CH or N,

n denotes 0, 1, 2, 3, 4 or 5 and

Hal denotes F, Cl, Br or I,

where, in the case that X has the meaning CH, R^2 and R^4 do not simultaneously denote H,

or a salt, enantiomer, or racemate thereof, or a mixture of enantiomers,

wherein at least one of the following three conditions I, II, or III is satisfied:

I) R^4 denotes H, Hal, CN, A or NO_2;

II) R^2 denotes H or alkyl;

III) Het is




O
OC (CH3)3
N
N
O
OC2H5
N
N
or
O
CH3
N
N
.